Imaging Study Using 18F-92AV45 and 11C-PIB PETCT to Detect Beta-Amyloid in Adults with Tau-Related Diseases and Malignant Tumors

What this Trial Is About

Researchers are evaluating the usefulness of a diagnostic imaging test called 18F-92AV45, 11C-PIB positron emission tomographycomputed tomography PETCT in patients with various Tau-related diseases, including primary and metastatic lesions. This study aims to better understand how well this PETCT scan can detect amyloid-related disease lesions, which are linked to neurodegenerative conditions. The trial is observational and includes adult patients with suspected or diagnosed malignant tumors related to amyloid diseases. Participants will receive a single intravenous injection of the 18F-92AV45, 11C-PIB tracer. After the injection, they will undergo a PETCT or MRI scan within a specified time frame to assess the presence of lesions. The uptake of the tracer in lesions will be measured using a standardized uptake value SUVmax, which helps quantify how much tracer is absorbed by the lesions. During the study, researchers will analyze the imaging results to determine the tests sensitivity, specificity, positive and negative predictive values, and overall accuracy in detecting lesions. Participants will be monitored for about 30 days, during which the standardized uptake value and diagnostic effectiveness will be the primary outcomes measured. The study includes adults aged 18 to 80 years and allows healthy volunteers to participate. Consent and assent are required according to ethical guidelines.

Beta Amyloid PET/CT in Various Aβ-Related Disease